CN1557295A - Gynecopathy therapeutic drug - Google Patents
Gynecopathy therapeutic drug Download PDFInfo
- Publication number
- CN1557295A CN1557295A CNA2004100258560A CN200410025856A CN1557295A CN 1557295 A CN1557295 A CN 1557295A CN A2004100258560 A CNA2004100258560 A CN A2004100258560A CN 200410025856 A CN200410025856 A CN 200410025856A CN 1557295 A CN1557295 A CN 1557295A
- Authority
- CN
- China
- Prior art keywords
- medicament
- treatment
- gossypol acetate
- gossypol
- gynaecopathia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940126585 therapeutic drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 53
- NIOHNDKHQHVLKA-UHFFFAOYSA-N acetic acid;7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)-2,3,8-trihydroxy-6-methyl-4-propan-2-ylnaphthalene-1-carbaldehyde Chemical compound CC(O)=O.CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 NIOHNDKHQHVLKA-UHFFFAOYSA-N 0.000 claims abstract description 46
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 12
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229920002472 Starch Polymers 0.000 claims abstract description 8
- 235000019698 starch Nutrition 0.000 claims abstract description 8
- 239000008107 starch Substances 0.000 claims abstract description 8
- 229920001353 Dextrin Polymers 0.000 claims abstract description 6
- 239000004375 Dextrin Substances 0.000 claims abstract description 6
- 235000019425 dextrin Nutrition 0.000 claims abstract description 6
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 6
- 239000001103 potassium chloride Substances 0.000 claims abstract description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 6
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 6
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 6
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 5
- 229960003495 thiamine Drugs 0.000 claims abstract description 5
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 5
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 5
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims description 52
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 28
- 201000009273 Endometriosis Diseases 0.000 claims description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 16
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 229960000583 acetic acid Drugs 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 7
- 208000007106 menorrhagia Diseases 0.000 claims description 7
- 210000000582 semen Anatomy 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 239000012362 glacial acetic acid Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 241000756943 Codonopsis Species 0.000 claims description 4
- 239000009636 Huang Qi Substances 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 238000001953 recrystallisation Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 10
- 238000002360 preparation method Methods 0.000 abstract description 8
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 54
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 description 27
- 229930000755 gossypol Natural products 0.000 description 27
- 229950005277 gossypol Drugs 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 230000003442 weekly effect Effects 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 230000002513 anti-ovulatory effect Effects 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 208000019025 Hypokalemia Diseases 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004696 endometrium Anatomy 0.000 description 4
- 210000004914 menses Anatomy 0.000 description 4
- 208000024896 potassium deficiency disease Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 238000007086 side reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003509 anti-fertility effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000007935 oral tablet Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000002893 slag Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- CZDZNZAJWBRTLE-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)-2,3,8-trihydroxy-6-methyl-4-propan-2-ylnaphthalene-1-carbaldehyde Chemical compound C=CN1CCCC1=O.CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 CZDZNZAJWBRTLE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108091060290 Chromatid Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010085330 Estradiol Receptors Proteins 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 206010047486 Virilism Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000004756 chromatid Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007731 hot pressing Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000804 nongenotoxic Toxicity 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012154 short term therapy Methods 0.000 description 1
- 230000009064 short-term regulation Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 208000025421 tumor of uterus Diseases 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to medicine preparation for treating women's diseases, and is especially medicine preparation containing gossypol acetate as main component for treating women's diseases. The medicine preparation contains gossypol acetate 3-5 wt%, potassium chloride 56-64 wt%, vitamin B1 2-3 wt%, vitamin B6 2-3 wt%, starch 12-15 wt% and dextrin 10-18 wt%. The medicine preparation has high curative effect, less side effect and low cost.
Description
Technical field: the present invention relates to a kind of medicament for the treatment of gynaecopathia, the medicament of the treatment gynaecopathia that particularly a kind of Main Ingredients and Appearance is a gossypol acetate.
Background technology:: gossypol from the seventies China this project as the case study of men's birth control medicine, by a large amount of research and experiment, gossypol is on probation first clinical from February, 1972 in Jiangsu, from then on acquisition has begun the clinical cooperative work of nationwide gossypol to the remarkable result of man's antifertility.Examination clothes 8806 examples gather by data altogether, and preparation gossypol antifertility effect is very remarkable, 5208 examples of wherein taking gossypol acetate, and effective percentage reaches 98.62%.But treat the gynopathic production that yet there are no with gossypol acetate, gynaecopathia is seriously perplexing numerous women, especially dysfunctional uterine hemorrhage, hysteromyoma, menorrhagia, endometriosis etc., according to domestic and international report, though treat these sick medicaments continuous listing is arranged, the gynaecopathia cure rate still has certain limit, some eutherapeutic medicament, the cost height, side effect is big, and the patient burden is heavy.
Summary of the invention: the purpose of this invention is to provide a kind of medicament for the treatment of gynaecopathia, its therapeutic effect is good, and side effect is little, production technology advanced person, and cost is low.
Technical scheme of the present invention: a kind of medicament for the treatment of gynaecopathia is provided, it is characterized in that: it mainly comprises gossypol acetate (C
32H
34O
10) and adjuvant; Gossypol acetate 3%-80% wherein.
Described adjuvant is starch and dextrin.
The medicament of described treatment gynaecopathia is: gossypol acetate 3%-5%; Potassium chloride 56%-64%; Vitamin B1 2%-3%; Vitamin B6 2%-3%; Starch 12%-15%; Dextrin 10%-18%.
The medicament of described treatment gynaecopathia is: gossypol acetate 5～20%; The Radix Astragali 15～50%; Radix Codonopsis 5～20%; Herba Leonuri 15～50%; Radix Angelicae Sinensis 5～20%; Herba Ecliptae 5～20%; Concha Ostreae 10～40%; Radix Curcumae 5～20%.
Described gossypol acetate (the C that mainly comprises
32H
34O
10) medicament, can be used for treating menorrhagia and hysteromyoma.
Described gossypol acetate (the C that mainly comprises
32H
34O
10) medicament, can be used for treating women's dysfunctional uterine hemorrhage.
Described gossypol acetate (the C that mainly comprises
32H
34O
10) medicament, can be used for treating cyclomastopathy.
Described gossypol acetate (the C that mainly comprises
32H
34O
10) medicament, can be used for the treatment and endometriosis.
The medicament production method of described treatment gynaecopathia is: the method with acetone hot reflux-acetic acid recrystallization extracts the gossypol acetate in the Semen Gossypii earlier, add adjuvant method routinely after the medicament mixed with gossypol acetate and other composition and make tablet or soft capsule, also can make drop pill or injection.
The method of described acetone hot reflux-acetic acid recrystallization is after Semen Gossypii is pulverized, put heat in the multi-function extractor 35 ℃-50 ℃ reflux, extract, 3-4 hour, extracting solution adds the cold crystallize of putting of glacial acetic acid, re-refine gossypol acetate.
Characteristics of the present invention: the medicament of this treatment gynaecopathia, mainly containing effective constituent is gossypol acetate, add adjuvant with purified gossypol acetate and make a kind of compound preparation of gynaecopathia for the treatment of for oral, its pharmacological action is: gossypol acetate can reduce endometrial cell slurry estradiol receptor quantity, reduces the estrogen organ to reactions female, progestogen; Also can act on ovary, ovarian hormone is descended, weaken negative feedback, strengthen pituitary function; Also suppress endometrial growth and prostaglandin thereof and generate, the cotton ketone of its metabolite can suppress the growth of body hormone.So can cause dysfunctional uterine hemorrhage patient atrophy of endometrium, inner membrance degeneration and short time amenorrhea.Gossypol acetate is a kind of complex salt of gossypol and acetic acid, and it has more safety, reliable, steady quality, gossypol acetate and potassium chloride; Vitamin B1, vitamin B6 mix preparation help to alleviate the side effect of gossypol and improve its stability, and the Radix Astragali, Radix Codonopsis, Herba Leonuri, Radix Angelicae Sinensis, Herba Ecliptae, Concha Ostreae, Radix Curcumae mix preparation are to treatment gynaecopathia better effects if.It not only is adapted to male contraception, also is highly suitable for women's dysfunctional uterine hemorrhage, hysteromyoma, cyclomastopathy, menorrhagia and endometriosis.Its gossypol acetate composition is produced by the hot pressing acetone after improving-acetic acid crystallization process, and is easy and simple to handle, utilization rate is high, cost is low, quality is good.
Gossypol is used as the interior disposable injection of rat uterine cavity with in the process of the test that reaches the antiearly pregnancy purpose, the Ultrastructural variation of endometrium and main organs.Test shows that rat endometrium epithelial cell, glandular cell, decidual cell all have damage in various degree.But gossypol is to the basic nonhazardous effect of rat internal organs cell, and the Change of Ultrastructure that causes of rat endometrium damaged cell, and majority is reversible, can progressively repair.The disposable in utero administration of evidence gossypol is a kind of more safe and effective antiearly pregnancy method, and function synthetic to ovary and the secretion progesterone does not have influence substantially.
Toxicological experiment: ameba Salmonella standard testing strain A98,100,1535,1537,1538, inductive rats'liver S9 activation system is not a mutagens.Take standard dose gossypol 30-48 month, nucleolar organizing region's number or acrocentric distributed did not have obviously influence.The not induced chromosome distortion of gossypol clinical dosage concentration.13 routine male take the gossypol 2 years of contraception dosage, compare with 12 example contrasts, and periphery lymphocyte micronucleus (MN) has rising slightly, but statistics is not remarkable.30 routine women take gossypol treatment in 6 months endometriosis, compare before and after taking medicine or with matched group, and their lymphocyte sister chromatids (SCE) is no significant difference all.Present evidence strong tendency is to finish its effect by the mechanism of a non-genotoxic in gossypol.
All more than 100ummol, promptly the high concentration gossypol interacts by enzyme relevant with the cell growth or functional protein and makes apoptosis deadly the gossypol concentration of inducing apoptosis of germ cells, the report of gossypol mutagenized cell neoplasm.At present do not find that as yet sexual cell has special apoptosis step, illustrate that sexual cell and somatic cell share same apoptosis mechanism.Imitate the rat test of human dosage form, the metabolism of discovery gossypol is to the normal diet group and lack all avirulence biochemical actions of protein energy group rat, and meaningfully gossypol and metabolite thereof have participated in reducing the metabolism of body inner cholesterol.Along with gossypol dosage increases and prolongs medicine time continuously, the hypokalemia time of origin shifts to an earlier date, and sickness rate also increases, and reduces the gossypol composition with potassium chloride, vitamin B1, vitamin B6 confection, can avoid hypokalemia and hypokalemia to take place.
Adopting gossypol-PVP effervescent tablet test, is that 25 times of amounts of human are included the rabbit intravaginal in dosage, and the result does not see that rabbit presents general toxic reaction.
The observed side reaction of relevant gossypol treatment gynaecopathia:
The medical college second Affiliated Hospital department of obstetrics and gynecology in Wuhan are used gossypol acetate and are treated 106 examples, patient's every day oral gossypol acetate 20mg, 1 month is 1 course of treatment, according to circumstances takes continuously 1-5 month, gossypol 0.54-2.7g is taken in accumulation.106 routine blood, routine urinalysis are all no abnormal.Person's 35 examples (33%) fully do not have no side effect.1 routine functional check ALT raises, and takes a turn for the better behind short term therapy.Serious side reaction appears in 5 examples (4.7%), and based on gastrointestinal symptom and weak, wherein 3 routine blood potassium are near lower bound, and it is not low that other 2 examples are burnt the obvious person's blood of hotness potassium.Once amenorrhea person's 62 examples, half drug withdrawal 3-6 month warp again naturally, multiple is patient more than 40 years old through the time above 6 months person overwhelming majority.Side reaction is many to be occurred 2-3 the course of treatment.
The specific embodiment
Extracting method:
Get Semen Gossypii and be pressed into dregs of rice pie, put in the multi-function extractor, in this multi-function extractor condensing unit is arranged, it can carry out the acetone hot reflux, and can extract volatile component.Doubly measure the aqueous acetone solution soak at room temperature 1 hour of 75-78% with volume 1-2, the 40 ℃ of reflux, extract, of heating again 3 hours are emitted acetone extract, the glacial acetic acid that adds 1/3 volume, mix the back and put 8 hours, separate out orange-yellow gossypol acetate, the crystallization of leaching crude product in the subzero essence.Discard residual solution behind the mother solution reclaim under reduced pressure acetone.Secondary is got in the aqueous acetone solution lixiviate of Semen Gossypii core slag reusable 75-80% emit acetone soln in above-mentioned production process after, and secondary raffinate is done following jar of extraction and applied mechanically, and useless cottonseed meal is by vapor recovery acetone; The acetone reusable that extracts, Semen Gossypii core slag are got oil and are made fertilizer.
Transform refining:
(1) gets the gossypol acetate crude product, with saturated, the filtration of an amount of dissolving of analytical pure acetone, under constantly stirring, add glacial acetic acid (analytical pure) and add in filtrate that solution is complete to become little turbid, place room temperature and change refrigerator 2 hours after 2 hours over to, with buchner funnel decompression leaching crystallization, with 30 ℃ of-60 ℃ of washings of a small amount of petroleum ether boiling range, promptly get more purified gossypol acetate.
(2) the above-mentioned gossypol acetate ether dissolution that does not contain peroxide that makes, filter, low temperature is below 55 ℃ or reduce pressure, concentrate the recovery ether, to original volume 2/3rds, the cooling back adds glacial acetic acid (analytical pure) and becomes little turbid to solution is complete under stirring condition, room temperature was placed 2 hours, relay refrigerator after 2 hours, with the buchner funnel leaching of reducing pressure, with 30 ℃ of-60 ℃ of washings of a small amount of petroleum ether boiling range, put the lucifuge place after doing, put into 40 ℃ of vacuum drying oven low temperature again, promptly got pure gossypol acetate in 4-8 hour in the vacuum under pressure drying of 0.05Mpa.
Getting medicament mixed after gossypol acetate that acetone-acid system makes and other composition are pulverized at last and add that supplementary product starch method routinely is synthetic makes tablet or injection, also can be soft capsule or drop pill.
The prescription of specific embodiment is as follows:
Embodiment 1: get gossypol acetate 100g, potassium chloride 2000g, 80g vitamin B1,80g vitamin B6, starch 500g, dextrin 300g and make 10000 as stated above altogether, cure mainly: dysfunctional uterine hemorrhage, hysteromyoma, menorrhagia, endometriosis.
The tablet of Application Example 1 treatment anovulatory dysfunctional uterine hemorrhage 32 examples, hysteromyoma bimonthly menses are through too much 57 examples, endometriosis 17 examples, and it counts 106 examples.Therapeutic scheme is 2 in an oral above-mentioned tablet, every day 2 times, once a day, according to circumstances successive administration 1-5 month, the result treated anovulatory dysfunctional uterine hemorrhage effective percentage 92.98%, treatment endometriosis effective percentage 100%, before 5 examples are used this medicines treatment in the endometriosis test group, once adopted pseudo pregnancy therapy treatment 2-4 month invalid, and 1 routine hypertension, 2 routine abnormal liver function (ALT rising), 2 examples are used testosterone propionate and are caused virilism.This illustrates that to a certain extent this medicine treatment endometriosis is better than pseudo pregnancy therapy.In 106 examples about 1/3rd patients to take medicine 1 month be onset, about 1/2nd patients onset in 2 months of taking medicine, only small number of patients need be taken medicine 4 months continuously.
Embodiment 2: get gossypol acetate 15%, the Radix Astragali 20%, Radix Codonopsis 5%, Herba Leonuri 20%, Radix Angelicae Sinensis 10%, Herba Ecliptae 6%, Concha Ostreae 14%, Radix Curcumae 10% by weight, make 10000 altogether.Cure mainly: dysfunctional uterine hemorrhage, uterus tumor, cyclomastopathy, menorrhagia, endometriosis.
Tablet treatment anovulatory dysfunctional uterine hemorrhage 36 examples of Application Example 2, hysteromyoma 6 examples, endometriosis 5 examples amount to 47 examples.Therapeutic scheme is oral tablets every day (20mg) a slice; Subtract 20mg after 60 days weekly until maintenance dose 2 times weekly, each 20mg; Kept 2-5 month.The result treats anovulatory dysfunctional uterine hemorrhage effective percentage 81.18%, treatment hysteromyoma effective percentage 83.3%, treatment endometriosis effective percentage 100%, to take medicine 1 month be onset to 17 examples in 47 examples, the onset in 2 months of taking medicine of 14 examples, the 10 examples onset in 3 months of taking medicine, only 2 examples need be taken medicine 4 months continuously.
The tablet treatment hysteromyoma bimonthly menses of Application Example 2 is through too much waiting gynaecopathia patient 53 examples, and oral tablets 1 time every day (20mg) changes maintenance dose 2 times weekly after 60 days, occur changing 1-2 time weekly after the amenorrhea, each 20mg; Kept altogether 6 months, total effective rate 84.9% as a result, and treatment hysteromyoma bimonthly menses is through too much effective percentage 84.4%.
Embodiment 3 makes 10000 tablets by weight synthesizing with gossypol acetate 76% supplementary product starch 24% method routinely.
Use gossypol treatment menorrhagia 148 examples, hysteromyoma 88 examples, endometriosis and gland flesh disease 26 examples amount to 262 examples, and therapeutic scheme is an oral gossypol acetate 1 time every day (20mg), changes maintenance dose after 60 days 2 times weekly, each 20mg, drug withdrawal after 3 months.Total effective rate 84.7% as a result, the treatment patients with uterine myoma, reduce in respect of efficient 93.2% by menstrual blood volume, dwindle in respect of efficient 36.4% by hysteromyoma, treatment endometriosis and gland flesh disease, take a turn for the better in respect of efficient 88.5% by dysmenorrhea, press rumpbone ligament tuberosity and touch a tender spot improvement in respect of efficient 84.6%.Treatment endometriosis and gland flesh disease are the shortest the course of treatment, and pain can alleviate in one month.Use gossypol treatment patients with uterine myoma 39 examples, total effective rate 87.18% is better than matched group.The control group medroxyprogestetone acetate treatment hysteromyoma 14 examples, total effective rate 50%
Treatment gynaecopathia patient 47 examples, patient's every day oral gossypol acetate 20mg, up to maintenance dose 2 times weekly, 20mg kept 2-5 month weekly.Slight dizziness, stomach poor appetite, nauseating, edema, weak appear in the initial partly patient that takes medicine, but the tolerance of patient's multipotency can disappear behind short-term regulation or the symptomatic treatment.Because of the conventional kalium replenishment 1g of test group, (3 times on the 1st), serious hypokalemia phenomenon appears in the end.Extremity were seriously unable after 1 example was taken medicine 3 months, changed maintenance dose into and continued kalium replenishment, transference cure.The maintenance dose of indivedual case histories changes into 1 time weekly, 20mg, and extend to 10-12 month total course of treatment, severe reaction do not occur.
In sum, gossypol treatment anovulatory dysfunctional uterine hemorrhage, hysteromyoma bimonthly menses are through too much and endometriosis, and fast, the short treating period of super effect all has superiority than operative treatment, androgen and pseudo pregnancy therapy.With " every days 20 gossypol dosage, 1 month be 1 course of treatment, auxiliary simultaneously kalium replenishment and polydipsia are eaten rich potassium; Carried out the treatment of second course of treatment in case of necessity at interval in 1 month again " be gynaecopathias such as therapeutic regimen, treatment endometriosis, be safe, relevant side effect is to alleviate or to cooperate the medicine of other composition avoidable.
Claims (10)
1, a kind of medicament for the treatment of gynaecopathia, it is characterized in that: it mainly comprises gossypol acetate (C
32H
34O
10) and adjuvant; Wherein gossypol acetate contains weight ratio 3%-80%.
2, a kind of medicament for the treatment of gynaecopathia according to claim 1, it is characterized in that: described adjuvant is starch and dextrin.
3, a kind of medicament for the treatment of gynaecopathia according to claim 1, it is characterized in that: described medicament contains gossypol acetate 3%-5%; Potassium chloride 56%-64%; Vitamin B1 2%-3%; Vitamin B6 2%-3%; Starch 12%-15%; Dextrin 10%-18%.
4, a kind of medicament for the treatment of gynaecopathia according to claim 1, it is characterized in that: described medicament contains gossypol acetate 5～20%; The Radix Astragali 15～50%; Radix Codonopsis 5～20%; Herba Leonuri 15～50%; Radix Angelicae Sinensis 5～20%; Herba Ecliptae 5～20%; Concha Ostreae 10～40%; Radix Curcumae 5～20%.
5, a kind of medicament for the treatment of gynaecopathia according to claim 1 is characterized in that: the described gossypol acetate (C that mainly comprises
32H
34O
10) medicament, can be used for treating menorrhagia and hysteromyoma.
6, a kind of medicament for the treatment of gynaecopathia according to claim 1 is characterized in that: the described gossypol acetate (C that mainly comprises
32H
34O
10) medicament, can be used for treating women's dysfunctional uterine hemorrhage.
7, a kind of medicament for the treatment of gynaecopathia according to claim 1 is characterized in that: the described gossypol acetate (C that mainly comprises
32H
34O
10) medicament, can be used for treating cyclomastopathy.
8, a kind of medicament for the treatment of gynaecopathia according to claim 1 is characterized in that: the described gossypol acetate (C that mainly comprises
32H
34O
10) medicament, can be used for treatment and endometriosis.
9, a kind of medicament for the treatment of gynaecopathia according to claim 1, its production method is: the method with acetone hot reflux-acetic acid recrystallization extracts the gossypol acetate in the Semen Gossypii earlier, add adjuvant method routinely after the medicament mixed with gossypol acetate and other composition and make tablet or soft capsule, also can make drop pill or injection.
10, a kind of medicament for the treatment of gynaecopathia according to claim 1, it is characterized in that: the method for described acetone hot reflux-acetic acid recrystallization is after Semen Gossypii is pulverized, put heat in the multi-function extractor 35 ℃-50 ℃ reflux, extract, 3-4 hour, extracting solution adds the cold crystallize of putting of glacial acetic acid, re-refine gossypol acetate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410025856 CN1245969C (en) | 2004-02-02 | 2004-02-02 | Gynecopathy therapeutic drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410025856 CN1245969C (en) | 2004-02-02 | 2004-02-02 | Gynecopathy therapeutic drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1557295A true CN1557295A (en) | 2004-12-29 |
| CN1245969C CN1245969C (en) | 2006-03-22 |
Family
ID=34352223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410025856 Expired - Lifetime CN1245969C (en) | 2004-02-02 | 2004-02-02 | Gynecopathy therapeutic drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1245969C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102144979A (en) * | 2011-03-03 | 2011-08-10 | 山东弘立医学动物实验研究有限公司 | frozen powder preparation for injection of L-gossypol or acetate of L-gossypol for treatment of tumor |
| CN111821288A (en) * | 2020-05-26 | 2020-10-27 | 新疆医科大学 | Active ingredient for preparing medicament for treating hysteromyoma and application thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102138916B (en) * | 2011-03-03 | 2012-05-23 | 山东弘立医学动物实验研究有限公司 | Levo-gossypol for treating tumors or cyclodextrin clathrate compound of acetate thereof |
-
2004
- 2004-02-02 CN CN 200410025856 patent/CN1245969C/en not_active Expired - Lifetime
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102144979A (en) * | 2011-03-03 | 2011-08-10 | 山东弘立医学动物实验研究有限公司 | frozen powder preparation for injection of L-gossypol or acetate of L-gossypol for treatment of tumor |
| CN102144979B (en) * | 2011-03-03 | 2012-05-23 | 山东弘立医学动物实验研究有限公司 | frozen powder preparation for injection of L-gossypol or acetate of L-gossypol for treatment of tumor |
| CN111821288A (en) * | 2020-05-26 | 2020-10-27 | 新疆医科大学 | Active ingredient for preparing medicament for treating hysteromyoma and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1245969C (en) | 2006-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103845348B (en) | 20 (R)-ginsenoside Rg3s application in preparation dysmenorrhea medicine | |
| NO325456B1 (en) | Use of an isoflavone-containing extract or composition containing the same for the preparation of a medicament for treating conditions associated with high activity of steroidal estrogens. | |
| Di Renzo et al. | Progesterone: History, facts, and artifacts | |
| CN101380440A (en) | Use of Yunkang oral liquid in preparing medicine for treating kidney-deficiency type sterility | |
| CN104107299A (en) | Traditional Chinese medicine mixture for treating dysmenorrhoea | |
| Chandeying et al. | Efficacy comparison of Pueraria mirifica (PM) against conjugated equine estrogen (CEE) with/without medroxyprogesterone acetate (MPA) in the treatment of climacteric symptoms in perimenopausal women: phase III study | |
| JPS6352013B2 (en) | ||
| CN100394936C (en) | Medicine for treating flooding and spotting and its preparation method | |
| CN1245969C (en) | Gynecopathy therapeutic drug | |
| CN102861148B (en) | Chinese medicine preparation for treating primary dysmenorrheal and preparation method and application | |
| CN102218127B (en) | Traditional Chinese medicine composition for treating dysmenorrhea and preparation method thereof | |
| CN104524105B (en) | Infertility, the Chinese medicine composition of menstrual disorder and its application with treatment luteal phase defect | |
| CN101879272B (en) | Chinese medicinal compound for treating coronary heart diseases, preparation method and application thereof | |
| US10548940B2 (en) | Pharmaceutical composition for controlling blood lipids and body weight, and use thereof | |
| CN110623993A (en) | Compound nutritional tablet of traditional Chinese medicine composition for treating gynecological inflammation and preparation method thereof | |
| Reifenstein Jr et al. | Artificial menstrual cycles induced in ovulating women by monthly injection of progestogen-estrogen | |
| CN102188580B (en) | Externally used traditional Chinese medicine composition and cataplasm for treating lobular hyperplasia of mammary gland, and preparation methods thereof | |
| Khan et al. | IMPORTANCE OF SHATAVARI CHURNA FOR FEMALES ACCORDING TO AYURVEDA | |
| CN111643511A (en) | Application of sophoricoside in preparing medicine for preventing and treating prostate disease | |
| JPS625126B2 (en) | ||
| CN101264270A (en) | Chinese medicinal composition for treating endometriosis symptoms and preparation thereof | |
| CN107582948B (en) | Pharmaceutical composition for treating female irregular menstruation and preparation method and application thereof | |
| CN102755624B (en) | Medicine for external use and for treating womb cold and preparation method thereof | |
| CN102512525B (en) | Traditional Chinese medicine composition for treating nonpregnant infertility of dairy cattle, and preparation method and use thereof | |
| KR20110089036A (en) | Functional food composition for treating infetility |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: SHAANXI PANLONG PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: SHANXI RDRAGON PHARMACEUTICAL GROUP CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 711400 Panlong eco industrial park, Zhashui County, Shaanxi Province Patentee after: SHAANXI PANLONG PHARMACEUTICAL GROUP LIMITED BY SHARE LTD. Address before: 711400 Panlong eco industrial park, Zhashui County, Shaanxi Province Patentee before: Shanxi Rdragon Pharmaceutical Group Co.,Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20060322 |
|
| CX01 | Expiry of patent term |